Cargando…

Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice

BACKGROUND: Liver aging is a significant risk factor for chronic liver diseases. Oxidative stress has been considered as a conjoint pathological mechanism for the initiation and progression of liver aging. It has been reported that d-galactose (d-gal)-induced hepatic injury is an experimental model...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jiaqi, Yu, Zepeng, Jing, Shu, Jiang, Weihai, Liu, Cong, Yu, Chunyan, Sun, Jinghui, Wang, Chunmei, Chen, Jianguang, Li, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174312/
https://www.ncbi.nlm.nih.gov/pubmed/30323572
http://dx.doi.org/10.2147/CIA.S173838
_version_ 1783361274474659840
author Gao, Jiaqi
Yu, Zepeng
Jing, Shu
Jiang, Weihai
Liu, Cong
Yu, Chunyan
Sun, Jinghui
Wang, Chunmei
Chen, Jianguang
Li, He
author_facet Gao, Jiaqi
Yu, Zepeng
Jing, Shu
Jiang, Weihai
Liu, Cong
Yu, Chunyan
Sun, Jinghui
Wang, Chunmei
Chen, Jianguang
Li, He
author_sort Gao, Jiaqi
collection PubMed
description BACKGROUND: Liver aging is a significant risk factor for chronic liver diseases. Oxidative stress has been considered as a conjoint pathological mechanism for the initiation and progression of liver aging. It has been reported that d-galactose (d-gal)-induced hepatic injury is an experimental model well established closely similar to morphological and functional features of liver aging. Schisandra sphenanthera Rehd. et Wils (S. sphenanthera, Schisandraceae), as a famous tradi-tional Chinese medicine, has been used for thousands of years in China to treat various disorders, including liver dysfunctions. This study was aimed to understand whether Anwulignan, one of the monomeric compounds in the lignans from S. sphenanthera, could improve the hepatic injury induced by d-gal in mice and to examine the possible mechanisms. METHODS: ICR mice were used to produce hepatic injury by 220 mg kg-1 d-gal subcutaneously once daily for 42 days. The effects of oral Anwulignan on liver index; serial AST and ALT levels; histological changes; SOD, GSH-Px, MDA, and 8-OHdG in the liver and peripheral blood; expression of p38 mitogen-activated protein kinase (MAPK), Nrf2, and HO-1 in the liver; and HepG2 cell viability, and decrease caspase-3 contents in liver were examined. RESULTS: Anwulignan could significantly increase the liver index, lower aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in the peripheral blood, elevate superoxide dis-mutase (SOD) and glutathione peroxidase (GSH-Px) activities, and decrease malonaldehyde (MDA) and 8-hydroxy-2-deoxyguanosine (8-OHdG) contents in the peripheral blood and liver. Furthermore, Anwulignan could upregulate the expression of p38 mitogen-activated protein kinase (MAPK), Nrf2, and HO-1 in the liver, increase the HepG2 cell viability, and decrease caspase-3 contents in liver. CONCLUSION: Anwulignan has protective effects against the hepatic injury induced by d-gal, which may be related to its antioxidant capacity through activating p38 MAPK–Nrf2–HO-1 pathway, increases the injured cell viability, and decreases the caspase-3 contents in liver.
format Online
Article
Text
id pubmed-6174312
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61743122018-10-15 Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice Gao, Jiaqi Yu, Zepeng Jing, Shu Jiang, Weihai Liu, Cong Yu, Chunyan Sun, Jinghui Wang, Chunmei Chen, Jianguang Li, He Clin Interv Aging Original Research BACKGROUND: Liver aging is a significant risk factor for chronic liver diseases. Oxidative stress has been considered as a conjoint pathological mechanism for the initiation and progression of liver aging. It has been reported that d-galactose (d-gal)-induced hepatic injury is an experimental model well established closely similar to morphological and functional features of liver aging. Schisandra sphenanthera Rehd. et Wils (S. sphenanthera, Schisandraceae), as a famous tradi-tional Chinese medicine, has been used for thousands of years in China to treat various disorders, including liver dysfunctions. This study was aimed to understand whether Anwulignan, one of the monomeric compounds in the lignans from S. sphenanthera, could improve the hepatic injury induced by d-gal in mice and to examine the possible mechanisms. METHODS: ICR mice were used to produce hepatic injury by 220 mg kg-1 d-gal subcutaneously once daily for 42 days. The effects of oral Anwulignan on liver index; serial AST and ALT levels; histological changes; SOD, GSH-Px, MDA, and 8-OHdG in the liver and peripheral blood; expression of p38 mitogen-activated protein kinase (MAPK), Nrf2, and HO-1 in the liver; and HepG2 cell viability, and decrease caspase-3 contents in liver were examined. RESULTS: Anwulignan could significantly increase the liver index, lower aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in the peripheral blood, elevate superoxide dis-mutase (SOD) and glutathione peroxidase (GSH-Px) activities, and decrease malonaldehyde (MDA) and 8-hydroxy-2-deoxyguanosine (8-OHdG) contents in the peripheral blood and liver. Furthermore, Anwulignan could upregulate the expression of p38 mitogen-activated protein kinase (MAPK), Nrf2, and HO-1 in the liver, increase the HepG2 cell viability, and decrease caspase-3 contents in liver. CONCLUSION: Anwulignan has protective effects against the hepatic injury induced by d-gal, which may be related to its antioxidant capacity through activating p38 MAPK–Nrf2–HO-1 pathway, increases the injured cell viability, and decreases the caspase-3 contents in liver. Dove Medical Press 2018-10-02 /pmc/articles/PMC6174312/ /pubmed/30323572 http://dx.doi.org/10.2147/CIA.S173838 Text en © 2018 Gao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Gao, Jiaqi
Yu, Zepeng
Jing, Shu
Jiang, Weihai
Liu, Cong
Yu, Chunyan
Sun, Jinghui
Wang, Chunmei
Chen, Jianguang
Li, He
Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice
title Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice
title_full Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice
title_fullStr Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice
title_full_unstemmed Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice
title_short Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice
title_sort protective effect of anwulignan against d-galactose-induced hepatic injury through activating p38 mapk–nrf2–ho-1 pathway in mice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174312/
https://www.ncbi.nlm.nih.gov/pubmed/30323572
http://dx.doi.org/10.2147/CIA.S173838
work_keys_str_mv AT gaojiaqi protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT yuzepeng protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT jingshu protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT jiangweihai protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT liucong protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT yuchunyan protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT sunjinghui protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT wangchunmei protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT chenjianguang protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice
AT lihe protectiveeffectofanwulignanagainstdgalactoseinducedhepaticinjurythroughactivatingp38mapknrf2ho1pathwayinmice